MAPT and dementia: Based on the available clinical, in vivo and in vitro evidence, it can be speculated that selective serotonin reuptake inhibitors (SSRIs), norepinephrine blockade agents, cholinesterase inhibitors, several other pharmacological compounds including PDE4 inhibitors, as well as non-pharmacological approaches such as physical exercise might be helpful in addressing MBI symptoms and dementia risk, at least partially via amyloid- and tau-related mechanisms.